Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test

PRINCETON, NJ and REHOVOT, Israel, via ETELIGIS INC., 09/03/2014 - - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the initiation of the Rosetta Cancer Origin Test™ Patient Registry study (COPR), a two-part global registry attempting to evaluate the impact of the Cancer Origin Test on treatment decisions in patients diagnosed with metastatic cancers or Cancers of Unknown or Uncertain Primary (CUP). COPR will also attempt to track treatments selected, duration of response to therapies, survival and other clinically relevant information including additional diagnostic testing performed.